LIGAND PHARMACEUTICALS INC short interest in 2026
In 2026, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 6.44% of shares outstanding on 15 Jan 2026 to 13.20% on 15 Sep 2026, a change of +6.76 percentage points. The year's high was 13.20% on 15 Sep 2026 and its low 6.44% on 15 Jan 2026, averaging 8.77% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.12 days on 31 Aug 2026. Full history: LIGAND PHARMACEUTICALS INC.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 6.44% (15 Jan 2026)
- End of year
- 13.20% (15 Sep 2026)
- Change
- +6.76 pp
- High
- 13.20% (15 Sep 2026)
- Low
- 6.44% (15 Jan 2026)
- Average
- 8.77%
- Highest days to cover
- 14.12 (31 Aug 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 6.44% | 4.55 | |
| 30 Jan 2026 | 6.52% | 6.49 | |
| 13 Feb 2026 | 6.97% | 6.93 | |
| 27 Feb 2026 | 6.91% | 9.02 | results (8-K), 10-K filed |
| 13 Mar 2026 | 7.32% | 5.76 | |
| 31 Mar 2026 | 7.50% | 6.45 | |
| 15 Apr 2026 | 7.05% | 5.26 | |
| 30 Apr 2026 | 7.30% | 7.97 | |
| 15 May 2026 | 7.51% | 6.67 | results (8-K), 10-Q filed |
| 29 May 2026 | 8.18% | 8.18 | |
| 15 Jun 2026 | 8.43% | 8.33 | |
| 30 Jun 2026 | 10.59% | 2.60 | |
| 15 Jul 2026 | 9.57% | 4.99 | |
| 31 Jul 2026 | 10.83% | 7.36 | |
| 14 Aug 2026 | 12.28% | 8.76 | results (8-K), 10-Q filed |
| 31 Aug 2026 | 12.44% | 14.12 | |
| 15 Sep 2026 | 13.20% | 13.53 |
See also: LIGAND PHARMACEUTICALS INC's full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.